Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression

Modern Pathology

Volumn 23, Issue 11, 2010, Pages 1518-1523

  Admirand, Joan H ^a   Knoblock, Ronald J ^a   Coombes, Kevin R ^a   Tam, Constantine ^a   Schlette, Ellen J ^a   Wierda, William G ^a   Ferrajoli, Alessandra ^a   O'Brien, Susan ^a   Keating, Michael J ^a   Luthra, Rajyalakshmi ^a   Medeiros, L Jeffrey ^a   Abruzzo, Lynne V ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

chronic lymphocytic leukemia; immunoglobulin heavy chain variable region genes; immunohistochemistry; QRT PCR; somatic mutation status; ZAP70

Indexed keywords

ALEMTUZUMAB; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; FLUDARABINE; MESSENGER RNA; PROTEIN KINASE ZAP 70; RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER GROWTH; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOMATIC MUTATION;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, IMMUNOGLOBULIN HEAVY CHAIN; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; TEXAS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 78049452623     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.131     Document Type: Article

References (20)

1. Schweighoffer E, Vanes L, Mathiot A, et al. Unexpected requirement for ZAP-70 in pre-B cell development and allelic exclusion. Immunity 2003;18: 523-533.
2. Admirand JH, Rassidakis GZ, Abruzzo LV, et al. Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. Mod Pathol 2004;17:954-961.
3. Carreras J, Villamor N, Colomo L, et al. Immunohisto-chemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. J Pathol 2005;205:507-513.
4. Sup SJ, Domiati-Saad R, Kelley TW, et al. ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL. Am J Clin Pathol 2004;122: 582-587.
5. Kipps TJ. Chronic lymphocytic leukemia. Curr Opin Hematol 2000;7:223-234.
6. McCarthy H, Wierda WG, Barron LL, et al. High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. Blood 2003;101:4903-4908.
7. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94: 1848-1854.
8. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363:105-111.
9. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-1775.
10. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944-4951.
11. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002;100:4609-4614.
12. Muller-Hermelink HKCD, Montserrat E, Harris NL. Chronic lymphocytic leukemia/small lymphocytic lymphoma In: Jaffe ES HN, Stein H, Vardiman JW (eds). Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue Vol. IARC Press: Lyon, 2001, pp, 127-130.
13. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997.
14. Thomas DA, O'Brien S, Giles FJ, et al. Single-agent rituximab in early-stage chronic lymphocytic leukemia. Oncology 2002;16:164a.
15. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893-901.
16. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998;102:1515-1525.
17. Oppezzo P, Vasconcelos Y, Settegrana C, et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 2005;106:650-657.
18. Krober A, Bloehdorn J, Hafner S, et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lympho-cytic leukemia. J Clin Oncol 2006;24:969-975.
19. Orchard J, Ibbotson R, Best G, et al. ZAP-70 in B cell malignancies. Leuk Lymphoma 2005;46:1689-1698.
20. Bakke AC, Purtzer Z, Leis J, et al. A robust ratio metric method for analysis of Zap-70 expression in chronic lymphocytic leukemia (CLL). Cytometry B Clin Cytom 2006;70:227-234.